P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.881
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P089 an EGFR KDD Data in the Chinese NSCLC Population and the Response to EGFR-TKIs: A Multicenter Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2005English

P1.13-13 Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy